SECsense Logo

Lixte Biotechnology's 8-K Report: Key Insights & Stock Updates (Feb 2025)

$LIXT
Form 8-K
Filed on: 2025-02-13
Source
Lixte Biotechnology's 8-K Report: Key Insights & Stock Updates (Feb 2025)

Based on the provided section of the financial report, here are the key insights and extracted information:

  1. Entity Information:
  • Company Name: Lixte Biotechnology Holdings, Inc.
  • CIK (Central Index Key): 0001335105
  • State of Incorporation: Delaware (DE)
  • SEC File Number: 001-39717
  • EIN (Employer Identification Number): 20-2903526
  • Address: 680 East Colorado Boulevard, Suite 180, Pasadena, CA 91101
  • Contact Number: (631) 830-7092
  1. Filing Type:
  • The document is classified as an 8-K filing, which typically reports unscheduled material events or corporate changes.
  1. Filing Date:
  • The report is dated February 11, 2025.
  1. Stock Information:
  • Common Stock Ticker Symbol: LIXT (listed on NASDAQ)
  • Warrants Ticker Symbol: LIXTW (listed on NASDAQ)
  1. Financial Context:
  • The report references various contexts, including common stock and warrants to purchase common stock.
  • The financial data is being reported as of February 11, 2025.
  1. Currency and Measurement Units:
  • All financial figures are reported in USD (United States Dollar).
  • There are also references to shares, indicating that the report may include information on stock structure or transactions involving shares.
  1. Regulatory Framework:
  • The report adheres to the US-GAAP (Generally Accepted Accounting Principles) standards, and the XBRL (eXtensible Business Reporting Language) format is utilized for structured data reporting.

Insights:

  • This 8-K filing indicates that Lixte Biotechnology is actively reporting specific corporate events as of a designated date, which may pertain to material changes in stock or warrants.
  • The presence of both common stock and warrants suggests potential financing activities or shareholder equity changes that are relevant to investors.
  • The inclusion of detailed identifiers and regulatory compliance signals the company's commitment to transparency and adherence to SEC regulations.

Conclusion:

Investors and stakeholders should review the complete filing for in-depth details regarding the specific events or transactions reported in this 8-K, as it may impact stock performance or corporate strategy.